Vall d'Hebron Talks by VHIR 'Quatsomes, a nanocarrier platform for delivering RNA-based therapies for cancer'

 Vall d'Hebron Talks by VHIR
  Sala d’actes de la planta baixa de l'edifici Collserola del VHIR — See in map
20/09/2023
20/09/2023 -- From 12:00h to 13:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: In-person
Share it:

Speaker: Dr. Ariadna Boloix Amenós, Main researcher Childhood Cancer and Blood Disorders (VHIR)

I am a postdoctoral researcher in the Neural tumors Laboratory  in the group of Childhood Cancer and Blood Disorders. Specifically, I am working on project based on the development and implementation of RNA-based therapies in clinical practice for the treatment of pediatric solid tumors.
Despite my Pharmacist background, I started my PhD in a collaboration between the Childhood Cancer and Blood Disorders group at VHIR and the Nanomol group at ICMAB-CSIC, focusing on developing a non-liposomal lipid nanocarrier for RNA delivery. After defending my thesis, I continued my work at VHIR, evaluating the effectiveness of the nanomedicine that we have developed from in vitro studies to in vivo models. My goal is to bridge the gap between cutting-edge research and practical clinical applications to benefit young patients.

RNA therapeutics have revolutionized cancer treatment by targeting the entire transcriptome. Small RNA molecules, such as microRNA (miRNA) and small interfering RNA (siRNA), are commonly used in preclinical and clinical settings. However, challenges in stability, biodistribution, and tissue targeting hinder their translation into effective treatments. Nanotechnology offers a promising solution to enhance the efficacy and selectivity of these therapies, particularly in targeting cancer cells. Lipid-based nanovesicles, including liposomes, have been extensively utilized for delivering nucleic acids and were among the first to reach the market. However, the lack of a standardized clinical formulation is a hurdle, mainly due to limited industrial-scale manufacturing capabilities and challenges in tissue specificity.
Our objective is to advance the development of a nanomedicine platform utilizing non-liposomal lipid-based nanovesicles known as Quatsomes (QS). This platform aims to deliver small RNAs with tumor-suppressive properties, ultimately improving cancer treatment.

Host: Dr. Miguel Segura Ginard, Main researcher Childhood Cancer and Blood Disorders (VHIR)

Related activities

Fira dels Somnis Balaguer 2025

Balaguer
05/04/2025 - 08:00
Solidarity initiatives
More information

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.